JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258911

Human IFI35 knockout A549 cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

IFI35 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon3 and 1 bp insertion in exon3.

View Alternative Names

FLJ21753, IFP 35, IN35_HUMAN, Interferon-induced 35 kDa protein, OTTHUMP00000236626, OTTHUMP00000236627

2 Images
Sanger Sequencing - Human IFI35 knockout A549 cell lysate (AB258911)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFI35 knockout A549 cell lysate (AB258911)

Allele-1 : 1 bp insertion in exon3

Sanger Sequencing - Human IFI35 knockout A549 cell lysate (AB258911)
  • Sanger seq

Unknown

Sanger Sequencing - Human IFI35 knockout A549 cell lysate (AB258911)

Allele-2 : 11 bp deletion in exon3

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon3 and 1 bp insertion in exon3.

Disease

Carcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258911-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human IFI35 knockout A549 cell lysate", "number":"AB258911-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type A549 cell lysate", "number":"AB258911-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
IFI35
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

IFI35 also known as Interferon-induced 35 kDa protein plays a role mechanically in the regulation of immune responses. It has a molecular mass of approximately 35 kDa. This protein is expressed in various tissues with high levels found in the liver lungs and spleen. IFI35 interacts with numerous proteins particularly within the cytoplasm to execute its functions.
Biological function summary

The protein modulates the innate immune system and interacts with other interferon-induced proteins. It forms a complex with NMI (N-Myc interactor) which stabilizes each other. Through these interactions IFI35 contributes to antiviral defense mechanisms and possibly acts in response to cellular stress.

Pathways

IFI35 engages in the interferon signaling pathway and the Jak-STAT pathway. These pathways play critical roles in mediating immune responses to viral infections. IFI35 works together with related proteins like STAT1 and NMI within these pathways providing a framework for antiviral activity and influence on cell survival.

IFI35 has associations with viral infections and autoimmune diseases. Viral pathogenesis can see modulation by IFI35 particularly infections caused by the hepatitis C virus. Furthermore its interaction with NMI may also play a part in autoimmune disorders by influencing inflammatory responses. These links highlight IFI35's significant contributions to disease mechanisms and therapeutic potential in managing immune-related conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com